Download
10456_2024_Article_9916.pdf 4,11MB
WeightNameValue
1000 Titel
  • Interleukin-6 drives endothelial glycocalyx damage in COVID-19 and bacterial sepsis
1000 Autor/in
  1. Drost, Carolin Christina |
  2. Rovas, Alexandros |
  3. Osiaevi, Irina |
  4. Schughart, Klaus |
  5. Lukasz, Alexander |
  6. Linke, Wolfgang A. |
  7. Pavenstädt, Hermann |
  8. Kümpers, Philipp |
1000 Verlag Springer Netherlands
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-10
1000 Erschienen in
1000 Quellenangabe
  • 27(3):411-422
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10456-024-09916-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303473/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Damage of the endothelial glycocalyx (eGC) plays a central role in the development of vascular hyperpermeability and organ damage during systemic inflammation. However, the specific signalling pathways for eGC damage remain poorly defined. Aim of this study was to combine sublingual video-microscopy, plasma proteomics and live cell imaging to uncover further pathways of eGC damage in patients with coronavirus disease 2019 (COVID-19) or bacterial sepsis. This secondary analysis of the prospective multicenter MICROCODE study included 22 patients with COVID-19 and 43 patients with bacterial sepsis admitted to intermediate or intensive care units and 10 healthy controls. Interleukin-6 (IL-6) was strongly associated with damaged eGC and correlated both with eGC dimensions (r<jats:sub>s</jats:sub>=0.36, <jats:italic>p</jats:italic> = 0.0015) and circulating eGC biomarkers. In vitro, IL-6 reduced eGC height and coverage, which was inhibited by blocking IL-6 signalling with the anti-IL-6 receptor antibody tocilizumab or the Janus kinase inhibitor tofacitinib. Exposure of endothelial cells to 5% serum from COVID-19 or sepsis patients resulted in a significant decrease in eGC height, which was attenuated by co-incubation with tocilizumab. In an external COVID-19 cohort of 219 patients from Massachusetts General Hospital, a previously identified proteomic eGC signature correlated with IL-6 (r<jats:sub>s</jats:sub>=-0.58, <jats:italic>p</jats:italic> &lt; 0.0001) and predicted the combined endpoint of 28-day mortality and/or intubation (ROC-AUC: 0.86 [95% CI: 0.81–0.91], <jats:italic>p</jats:italic> &lt; 0.001). The data suggest that IL-6 may significantly drive eGC damage in COVID-19 and bacterial sepsis. Our findings provide valuable insights into pathomechanisms of vascular dysfunction during systemic inflammation and highlight the need for further in vivo studies.</jats:p>
1000 Sacherschließung
lokal Endothelial Cells/pathology [MeSH]
gnd 1206347392 COVID-19
lokal Heparanase
lokal Aged [MeSH]
lokal Glycocalyx/pathology [MeSH]
lokal COVID-19/complications [MeSH]
lokal COVID-19/pathology [MeSH]
lokal Sepsis/pathology [MeSH]
lokal Antibodies, Monoclonal, Humanized [MeSH]
lokal Glycocalyx/metabolism [MeSH]
lokal Male [MeSH]
lokal Sepsis
lokal SARS-CoV-2/metabolism [MeSH]
lokal Sepsis/metabolism [MeSH]
lokal Interleukin-6/metabolism [MeSH]
lokal Endothelial Cells/metabolism [MeSH]
lokal Female [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal COVID-19
lokal Endothelial glycocalyx
lokal Sepsis/complications [MeSH]
lokal Original Paper
lokal COVID-19/metabolism [MeSH]
lokal Sublingual microscopy
lokal Interleukin-6/blood [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RHJvc3QsIENhcm9saW4gQ2hyaXN0aW5h|https://frl.publisso.de/adhoc/uri/Um92YXMsIEFsZXhhbmRyb3M=|https://frl.publisso.de/adhoc/uri/T3NpYWV2aSwgSXJpbmE=|https://frl.publisso.de/adhoc/uri/U2NodWdoYXJ0LCBLbGF1cw==|https://frl.publisso.de/adhoc/uri/THVrYXN6LCBBbGV4YW5kZXI=|https://frl.publisso.de/adhoc/uri/TGlua2UsIFdvbGZnYW5nIEEu|https://frl.publisso.de/adhoc/uri/UGF2ZW5zdMOkZHQsIEhlcm1hbm4=|https://frl.publisso.de/adhoc/uri/S8O8bXBlcnMsIFBoaWxpcHA=
1000 Hinweis
  • DeepGreen-ID: 94d95aa514584b81b4cae2e0a151444f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Münster |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Münster |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6504681.rdf
1000 Erstellt am 2025-02-06T03:13:12.623+0100
1000 Erstellt von 322
1000 beschreibt frl:6504681
1000 Zuletzt bearbeitet 2025-08-05T07:36:00.793+0200
1000 Objekt bearb. Tue Aug 05 07:36:00 CEST 2025
1000 Vgl. frl:6504681
1000 Oai Id
  1. oai:frl.publisso.de:frl:6504681 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source